Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07098884
Recruiting Observational

Artificial Intelligence for Pathology Diagnosis and Prognosis Prediction of Lung Nodule Using Smartphone Photos

NCT07098884 · tracked via the Priya Life Science China tracker
Sponsor
Anhui Provincial Hospital
Phase
Observational
Started
2025-06-01
Last updated
2025-08-01

Condition(s) studied

Artificial IntelligenceLung Nodule

Investigational drug(s) / intervention(s)

AI model

AI model: AI model developed by smartphone photos of resected tumor specimens

Study summary

The current study aims to develop and validate a deep learning signature for diagnosing pathology and predicting prognosis of lung nodule using smartphone photos of resected tumor specimens.

Eligibility

Sex
ALL
Min age
20 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: (1) Participants scheduled for surgery for radiological finding of pulmonary lesions from the preoperative thin-section CT scans; (2) Age ranging from 20-75 years. Exclusion Criteria: (1) Participants with incomplete clinical information; (2) Participants who have received anti-tumor therapy.

Primary outcome measure(s)

  • Area under the receiver operating characteristic curve — From enrollment to the end of the study, assessed up to 6 months

Trial sites (3)

FacilityCityRegionStatus
Anhui Provincial Hospital Hefei Anhui Recruiting
The First Affiliated Hospital of Soochow University Suzhou Jiangsu Recruiting
Ningbo First Hospital Ningbo Zhejiang Recruiting

More Anhui Provincial Hospital trials in China

A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites Starting soon
Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer Recruiting
China Metastatic Liver Cancer Clinical Registry Cohort Database Recruiting
Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases Recruiting
Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study Starting soon

Other trials for the same condition

Real-world of AI in Diagnosing Retinal Diseases Recruiting
Effect of the Automatic Surveillance System on Surveillance Rate of Patients with Gastric Premalignant Lesions Recruiting
AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors Recruiting
AI-based Low Dose CBCT Reconstruction for Clinical Application Starting soon
Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07098884 on ClinicalTrials.gov ↗ ← All trials in China